Scientists Identify Immune Cells That May Explain Why Type 1 Diabetes Persists

One of the puzzles researchers have grappled with in type 1 diabetes is not just why the immune system mistakenly attacks insulin-producing beta cells—but how that attack keeps going for years, even decades. A new study offers potential insight into this persistence by identifying a population of unusual immune cells that may act as a reservoir fueling the ongoing immune response.

Scientists examined pancreatic lymph nodes from people with type 1 diabetes using advanced techniques including mass cytometry, single-cell RNA sequencing, and T-cell receptor profiling. Pancreatic lymph nodes are strategically located near the pancreas and serve as a critical meeting point between the immune system and pancreatic tissue.

The research team found increased numbers of stem-cell-memory-like CD8 T cells in these lymph nodes. What makes these cells notable is their dual ability: they can renew themselves while also producing more specialized T cells. This self-renewal capacity suggests they could act as a persistent reservoir, continuously fueling the immune attack over long periods.

Analysis of the immune cells pointed to IL-15 signaling as one pathway that may help drive and maintain this immune state. IL-15 is a molecule that helps regulate immune cell behavior, and identifying it as potentially involved in sustaining these stem-like cells opens a new avenue for future research.

Researchers also found related effector CD8 T cells in both the pancreatic lymph nodes and inside the pancreatic tissue itself. The cells located within the pancreas showed stronger characteristics of becoming terminal immune effectors—specialized killer cells focused on their target.

This research helps explain a fundamental question: how does type 1 diabetes remain active over time? By identifying stem-like immune cells with self-renewal capacity as a likely driver of persistence, scientists have pinpointed a potential weak point in the immune system's sustained attack. Future work could explore whether targeting these cells or the IL-15 pathway might interrupt the long-term immune response, though much more research is needed before any potential treatments could reach people with type 1 diabetes.

Origin: diabetes.co.uk (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.